Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amnesia D000647 12 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Anthrax D000881 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthus Reaction D001183 8 associated lipids
Ascites D001201 25 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Mueller HW et al. 1-O-alkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1984 J. Lipid Res. pmid:6427378
Kamitani T et al. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. 1984 Eur. J. Pharmacol. pmid:6144557
Tokumura A et al. Contractile effect of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine on strips of isolated rat intestine. 1984 J. Pharm. Pharmacol. pmid:6144763
Pirotzky E et al. Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. 1984 Kidney Int. pmid:6144811
Gómez-Cambronero J et al. The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). 1984 Biochem. J. pmid:6146309
Knauer KA et al. Platelet augmentation of IgE-dependent histamine release from human basophils and mast cells. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6200443
Kazimierczak W et al. Deuterium-oxide-induced histamine release from basophils of allergic subjects. I. Responsiveness to deuterium oxide requires an activation step. 1984 Am. Rev. Respir. Dis. pmid:6201094
O'Flaherty JT et al. Diacylglycerols enhance human neutrophil degranulation responses: relevancy to a multiple mediator hypothesis of cell function. 1984 Biochem. Biophys. Res. Commun. pmid:6433920
Mendlovic F et al. Possible involvement of cyclooxygenase products in the actions of platelet-activating factor and of lipoxygenase products in the vascular effects of epinephrine in perfused rat liver. 1984 Biochem. Biophys. Res. Commun. pmid:6435614
Malpass TW et al. The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. 1984 J. Thorac. Cardiovasc. Surg. pmid:6231433
Willoughby WF and Willoughby JB Immunologic mechanisms of parenchymal lung injury. 1984 Environ. Health Perspect. pmid:6234162
Fouque F and Vargaftig BB Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. 1984 Br. J. Pharmacol. pmid:6439269
Karlsson G and Pipkorn U Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. 1984 Eur. J. Clin. Pharmacol. pmid:6439565
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Nagata K et al. [Thrombotic thrombocytopenic purpura (TTP) with a remission following splenectomy after the failure of antiplatelet therapy and plasmapheresis]. 1984 Rinsho Ketsueki pmid:6542941
Pirotzky E et al. PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. 1984 Microcirc Endothelium Lymphatics pmid:6546141
Smith RJ et al. Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. 1984 Biochem. Pharmacol. pmid:6324816
Buxton DB et al. Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine. 1984 J. Biol. Chem. pmid:6693418
Sakamoto H et al. Stimulation of leukocyte phagocytic activity by the platelet release reaction. 1984 Pathology pmid:6462776
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Doebber TW et al. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6517949
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Caramelo C et al. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. 1984 Biochem. Biophys. Res. Commun. pmid:6732788
Lenihan DJ and Lee TC Regulation of platelet activating factor synthesis: modulation of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase by phosphorylation and dephosphorylation in rat spleen microsomes. 1984 Biochem. Biophys. Res. Commun. pmid:6732789
Ludwig JC et al. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular Ca2+. 1984 Arch. Biochem. Biophys. pmid:6430234
Kasuya Y et al. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. 1984 Can. J. Physiol. Pharmacol. pmid:6733593
Page CP et al. Platelets and bronchospasm. 1984 Int. Arch. Allergy Appl. Immunol. pmid:6735490
Jouvin-Marche E et al. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. 1984 J. Immunol. pmid:6736649
Pipkorn U et al. Effect of platelet activating factor on the human nasal mucosa. 1984 Allergy pmid:6703263
Lüthje J and Ogilvie A Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP. 1984 Biochem. Biophys. Res. Commun. pmid:6704102
Clare KA and Scrutton MC The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). 1984 Eur. J. Biochem. pmid:6705791
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Kester M et al. The potentiation of arterial contraction with platelet activating factor. 1984 Pflugers Arch. pmid:6718228
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Guay DR and Richard A Heparin-induced thrombocytopenia--association with a platelet aggregating factor and cross-sensitivity to bovine and porcine heparin. 1984 Drug Intell Clin Pharm pmid:6723517
Poitevin B et al. Paf-acether generates chemiluminescence in human neutrophils in the absence of cytochalasin B. 1984 Immunopharmacology pmid:6724877
Kasuya Y et al. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). 1984 J. Pharmacobio-dyn. pmid:6726619
Archer CB et al. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. 1984 Prostaglandins pmid:6203139
Schlondorff D et al. Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. 1984 J. Clin. Invest. pmid:6423667
Gunby P A new piece for the puzzle of inflammation. 1984 JAMA pmid:6420583
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930
Billah MM and Siegel MI Calmodulin antagonists inhibit formation of platelet-activating factor in stimulated human neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6422930
Prevost MC et al. Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. 1984 Biochem. Biophys. Res. Commun. pmid:6422938